Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

California’s Prop 61 Fails, But More Pricing Measures Could Be Ahead

Nov 09 2016

• By Joseph Haas

vote election badge 2016_1200x675

Related Content

President Trump And Drug Pricing: What To Expect

Nov 09 2016

What Does The Trump Victory Mean For Pharma In Post-Referendum EU?

Nov 09 2016

President Trump And Drug Pricing: What To Expect

Nov 09 2016

Trump’s ACA Repeal: What’s In It For Biopharma?

Nov 09 2016

Pharma Is Ready And Waiting For A Tax Holiday Under Trump

Nov 09 2016

Calif. Prop 61 Raises Industry Concerns Over Ripple Effect

Nov 02 2016

Additional Topics

Government Payers Market Access Policy Pricing Debate Elections BioPharmaceutical

More from Government Payers

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window